Review



opg  (Bioss)


Bioz Verified Symbol Bioss is a verified supplier
Bioz Manufacturer Symbol Bioss manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Bioss opg
    Opg, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 39 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/opg/product/Bioss
    Average 94 stars, based on 39 article reviews
    opg - by Bioz Stars, 2026-03
    94/100 stars

    Images



    Similar Products

    94
    Guangzhou JET Bio-Filtration human opg (osteoprotegerin) elisa kit
    Human Opg (Osteoprotegerin) Elisa Kit, supplied by Guangzhou JET Bio-Filtration, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human opg (osteoprotegerin) elisa kit/product/Guangzhou JET Bio-Filtration
    Average 94 stars, based on 1 article reviews
    human opg (osteoprotegerin) elisa kit - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    93
    MedChemExpress recombinant human tr11b protein medchemexpress cat
    Recombinant Human Tr11b Protein Medchemexpress Cat, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human tr11b protein medchemexpress cat/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    recombinant human tr11b protein medchemexpress cat - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    94
    Proteintech opg
    COL-I, OCN, <t>OPG</t> and RANKL protein expression levels in each group after 8 weeks of intervention. (A) COL-I, OCN, OPG and RANKL protein expression level of each treatment group. Average optical density of (B) COL-I, (C) OCN, (D) OPG and (E) RANKL in each group. *P<0.05 vs. Ctrl group; # P<0.05 vs. T2DM model group. COL-I, type I collagen; <t>OCN,</t> <t>osteocalcin;</t> OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-κB ligand; Ctrl, control; T2DM, type 2 diabetes mellitus; ZnC, zinc carnosine; AOD, average optical density value.
    Opg, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/opg/product/Proteintech
    Average 94 stars, based on 1 article reviews
    opg - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    93
    Multi Sciences (Lianke) Biotech Co Ltd human tr11b elisa kit multisciences cat
    COL-I, OCN, <t>OPG</t> and RANKL protein expression levels in each group after 8 weeks of intervention. (A) COL-I, OCN, OPG and RANKL protein expression level of each treatment group. Average optical density of (B) COL-I, (C) OCN, (D) OPG and (E) RANKL in each group. *P<0.05 vs. Ctrl group; # P<0.05 vs. T2DM model group. COL-I, type I collagen; <t>OCN,</t> <t>osteocalcin;</t> OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-κB ligand; Ctrl, control; T2DM, type 2 diabetes mellitus; ZnC, zinc carnosine; AOD, average optical density value.
    Human Tr11b Elisa Kit Multisciences Cat, supplied by Multi Sciences (Lianke) Biotech Co Ltd, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human tr11b elisa kit multisciences cat/product/Multi Sciences (Lianke) Biotech Co Ltd
    Average 93 stars, based on 1 article reviews
    human tr11b elisa kit multisciences cat - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    opg  (Bioss)
    94
    Bioss opg
    COL-I, OCN, <t>OPG</t> and RANKL protein expression levels in each group after 8 weeks of intervention. (A) COL-I, OCN, OPG and RANKL protein expression level of each treatment group. Average optical density of (B) COL-I, (C) OCN, (D) OPG and (E) RANKL in each group. *P<0.05 vs. Ctrl group; # P<0.05 vs. T2DM model group. COL-I, type I collagen; <t>OCN,</t> <t>osteocalcin;</t> OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-κB ligand; Ctrl, control; T2DM, type 2 diabetes mellitus; ZnC, zinc carnosine; AOD, average optical density value.
    Opg, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/opg/product/Bioss
    Average 94 stars, based on 1 article reviews
    opg - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    93
    Cusabio opg elisa kit
    Depletion of miR-185 in MLO-Y4 cells reduces the osteoclastogenic potential of RAW264.7 cells. ( A ) The levels of soluble RANKL (sRANKL) and osteoprotegerin <t>(OPG)</t> in the serum of WT and miR-185 KO mice were quantified by <t>ELISA</t> ( n = 3). ( B ) The concentrations of sRANKL and OPG in conditioned medium from WT and miR-185 KO MLO-Y4 cells were measured by ELISA ( n = 3). ( C ) RAW264.7 cells were co-cultured for 4 days with conditioned medium derived from miR-185 KO, sh Arl8b , and corresponding control MLO-Y4 cells, supplemented with 50 ng/mL RANKL and 30 ng/mL M-CSF ( n = 3). After 4 days of culture, qPCR was performed to evaluate mRNA expression levels of osteoclast marker genes, including Trap , DC-stamp , Ctsk , and Nfatc1 . ( D ) Representative images of tartrate-resistant acid phosphatase (TRAP)-stained osteoclast cultures ( n = 3). ( E ) TRAP-positive cells were counted based on the number of nuclei. ( F ) TRAP-positive multinucleated cells (containing > 3 nuclei) were quantified. ( G ) Cathepsin K (CTSK), a marker of osteoclasts, was detected by western blotting ( n = 3). ( H ) The mRNA expression of matrix metalloproteinase 14 ( Mmp14 ) in MLO-Y4 cells was measured by RT-qPCR ( n = 3). ( I , J ) The protein levels of MMP14 in MLO-Y4 cells were evaluated by western blotting. ( K ) Quantitative analysis of MMP14 protein expression was performed using ImageJ software. ( L )The mRNA expression of Mmp14 in the femurs of mice was assessed by qPCR ( n = 3). Data represent at least three independent experiments and are shown as mean ± S.D. (ns, not significant, * p < 0.05, ** p < 0.01, *** p < 0.001). The full-length blot is presented in supplementary Raw Western
    Opg Elisa Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/opg elisa kit/product/Cusabio
    Average 93 stars, based on 1 article reviews
    opg elisa kit - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    opg  (Biorbyt)
    93
    Biorbyt opg
    Depletion of miR-185 in MLO-Y4 cells reduces the osteoclastogenic potential of RAW264.7 cells. ( A ) The levels of soluble RANKL (sRANKL) and osteoprotegerin <t>(OPG)</t> in the serum of WT and miR-185 KO mice were quantified by <t>ELISA</t> ( n = 3). ( B ) The concentrations of sRANKL and OPG in conditioned medium from WT and miR-185 KO MLO-Y4 cells were measured by ELISA ( n = 3). ( C ) RAW264.7 cells were co-cultured for 4 days with conditioned medium derived from miR-185 KO, sh Arl8b , and corresponding control MLO-Y4 cells, supplemented with 50 ng/mL RANKL and 30 ng/mL M-CSF ( n = 3). After 4 days of culture, qPCR was performed to evaluate mRNA expression levels of osteoclast marker genes, including Trap , DC-stamp , Ctsk , and Nfatc1 . ( D ) Representative images of tartrate-resistant acid phosphatase (TRAP)-stained osteoclast cultures ( n = 3). ( E ) TRAP-positive cells were counted based on the number of nuclei. ( F ) TRAP-positive multinucleated cells (containing > 3 nuclei) were quantified. ( G ) Cathepsin K (CTSK), a marker of osteoclasts, was detected by western blotting ( n = 3). ( H ) The mRNA expression of matrix metalloproteinase 14 ( Mmp14 ) in MLO-Y4 cells was measured by RT-qPCR ( n = 3). ( I , J ) The protein levels of MMP14 in MLO-Y4 cells were evaluated by western blotting. ( K ) Quantitative analysis of MMP14 protein expression was performed using ImageJ software. ( L )The mRNA expression of Mmp14 in the femurs of mice was assessed by qPCR ( n = 3). Data represent at least three independent experiments and are shown as mean ± S.D. (ns, not significant, * p < 0.05, ** p < 0.01, *** p < 0.001). The full-length blot is presented in supplementary Raw Western
    Opg, supplied by Biorbyt, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/opg/product/Biorbyt
    Average 93 stars, based on 1 article reviews
    opg - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    93
    BioVendor Instruments opg biovendor
    Depletion of miR-185 in MLO-Y4 cells reduces the osteoclastogenic potential of RAW264.7 cells. ( A ) The levels of soluble RANKL (sRANKL) and osteoprotegerin <t>(OPG)</t> in the serum of WT and miR-185 KO mice were quantified by <t>ELISA</t> ( n = 3). ( B ) The concentrations of sRANKL and OPG in conditioned medium from WT and miR-185 KO MLO-Y4 cells were measured by ELISA ( n = 3). ( C ) RAW264.7 cells were co-cultured for 4 days with conditioned medium derived from miR-185 KO, sh Arl8b , and corresponding control MLO-Y4 cells, supplemented with 50 ng/mL RANKL and 30 ng/mL M-CSF ( n = 3). After 4 days of culture, qPCR was performed to evaluate mRNA expression levels of osteoclast marker genes, including Trap , DC-stamp , Ctsk , and Nfatc1 . ( D ) Representative images of tartrate-resistant acid phosphatase (TRAP)-stained osteoclast cultures ( n = 3). ( E ) TRAP-positive cells were counted based on the number of nuclei. ( F ) TRAP-positive multinucleated cells (containing > 3 nuclei) were quantified. ( G ) Cathepsin K (CTSK), a marker of osteoclasts, was detected by western blotting ( n = 3). ( H ) The mRNA expression of matrix metalloproteinase 14 ( Mmp14 ) in MLO-Y4 cells was measured by RT-qPCR ( n = 3). ( I , J ) The protein levels of MMP14 in MLO-Y4 cells were evaluated by western blotting. ( K ) Quantitative analysis of MMP14 protein expression was performed using ImageJ software. ( L )The mRNA expression of Mmp14 in the femurs of mice was assessed by qPCR ( n = 3). Data represent at least three independent experiments and are shown as mean ± S.D. (ns, not significant, * p < 0.05, ** p < 0.01, *** p < 0.001). The full-length blot is presented in supplementary Raw Western
    Opg Biovendor, supplied by BioVendor Instruments, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/opg biovendor/product/BioVendor Instruments
    Average 93 stars, based on 1 article reviews
    opg biovendor - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    Image Search Results


    COL-I, OCN, OPG and RANKL protein expression levels in each group after 8 weeks of intervention. (A) COL-I, OCN, OPG and RANKL protein expression level of each treatment group. Average optical density of (B) COL-I, (C) OCN, (D) OPG and (E) RANKL in each group. *P<0.05 vs. Ctrl group; # P<0.05 vs. T2DM model group. COL-I, type I collagen; OCN, osteocalcin; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-κB ligand; Ctrl, control; T2DM, type 2 diabetes mellitus; ZnC, zinc carnosine; AOD, average optical density value.

    Journal: Molecular Medicine Reports

    Article Title: Effects of zinc carnosine on bone loss in mice with diabetic osteoporosis

    doi: 10.3892/mmr.2025.13723

    Figure Lengend Snippet: COL-I, OCN, OPG and RANKL protein expression levels in each group after 8 weeks of intervention. (A) COL-I, OCN, OPG and RANKL protein expression level of each treatment group. Average optical density of (B) COL-I, (C) OCN, (D) OPG and (E) RANKL in each group. *P<0.05 vs. Ctrl group; # P<0.05 vs. T2DM model group. COL-I, type I collagen; OCN, osteocalcin; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-κB ligand; Ctrl, control; T2DM, type 2 diabetes mellitus; ZnC, zinc carnosine; AOD, average optical density value.

    Article Snippet: The primary antibodies used and their dilution ratios are as follows: Type I collagen (COL-I; 1:200; cat. no. AF7001; Affinity Biosciences), osteocalcin (OCN, 1:200; cat. no. 16157-1-AP; Proteintech Group, Inc.) and OPG (1:200; cat. no 31766-1-AP; Proteintech Group, Inc.).

    Techniques: Expressing, Control

    mRNA expression levels of bone metabolism-related factors. *P<0.05 and ***P<0.01 vs. Ctrl group; ## P<0.01 vs. T2DM model group. (A) Ctrl, control; (B) T2DM, type 2 diabetes mellitus; (C) ZnC, zinc carnosine. OCN, osteocalcin; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-κB ligand.

    Journal: Molecular Medicine Reports

    Article Title: Effects of zinc carnosine on bone loss in mice with diabetic osteoporosis

    doi: 10.3892/mmr.2025.13723

    Figure Lengend Snippet: mRNA expression levels of bone metabolism-related factors. *P<0.05 and ***P<0.01 vs. Ctrl group; ## P<0.01 vs. T2DM model group. (A) Ctrl, control; (B) T2DM, type 2 diabetes mellitus; (C) ZnC, zinc carnosine. OCN, osteocalcin; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-κB ligand.

    Article Snippet: The primary antibodies used and their dilution ratios are as follows: Type I collagen (COL-I; 1:200; cat. no. AF7001; Affinity Biosciences), osteocalcin (OCN, 1:200; cat. no. 16157-1-AP; Proteintech Group, Inc.) and OPG (1:200; cat. no 31766-1-AP; Proteintech Group, Inc.).

    Techniques: Expressing, Control

    Depletion of miR-185 in MLO-Y4 cells reduces the osteoclastogenic potential of RAW264.7 cells. ( A ) The levels of soluble RANKL (sRANKL) and osteoprotegerin (OPG) in the serum of WT and miR-185 KO mice were quantified by ELISA ( n = 3). ( B ) The concentrations of sRANKL and OPG in conditioned medium from WT and miR-185 KO MLO-Y4 cells were measured by ELISA ( n = 3). ( C ) RAW264.7 cells were co-cultured for 4 days with conditioned medium derived from miR-185 KO, sh Arl8b , and corresponding control MLO-Y4 cells, supplemented with 50 ng/mL RANKL and 30 ng/mL M-CSF ( n = 3). After 4 days of culture, qPCR was performed to evaluate mRNA expression levels of osteoclast marker genes, including Trap , DC-stamp , Ctsk , and Nfatc1 . ( D ) Representative images of tartrate-resistant acid phosphatase (TRAP)-stained osteoclast cultures ( n = 3). ( E ) TRAP-positive cells were counted based on the number of nuclei. ( F ) TRAP-positive multinucleated cells (containing > 3 nuclei) were quantified. ( G ) Cathepsin K (CTSK), a marker of osteoclasts, was detected by western blotting ( n = 3). ( H ) The mRNA expression of matrix metalloproteinase 14 ( Mmp14 ) in MLO-Y4 cells was measured by RT-qPCR ( n = 3). ( I , J ) The protein levels of MMP14 in MLO-Y4 cells were evaluated by western blotting. ( K ) Quantitative analysis of MMP14 protein expression was performed using ImageJ software. ( L )The mRNA expression of Mmp14 in the femurs of mice was assessed by qPCR ( n = 3). Data represent at least three independent experiments and are shown as mean ± S.D. (ns, not significant, * p < 0.05, ** p < 0.01, *** p < 0.001). The full-length blot is presented in supplementary Raw Western

    Journal: Stem Cell Research & Therapy

    Article Title: Depletion of mmu-miR-185 enhances osteocyte connectivity and suppresses bone fragility through the interaction between ARL8B and RAB5A

    doi: 10.1186/s13287-025-04612-y

    Figure Lengend Snippet: Depletion of miR-185 in MLO-Y4 cells reduces the osteoclastogenic potential of RAW264.7 cells. ( A ) The levels of soluble RANKL (sRANKL) and osteoprotegerin (OPG) in the serum of WT and miR-185 KO mice were quantified by ELISA ( n = 3). ( B ) The concentrations of sRANKL and OPG in conditioned medium from WT and miR-185 KO MLO-Y4 cells were measured by ELISA ( n = 3). ( C ) RAW264.7 cells were co-cultured for 4 days with conditioned medium derived from miR-185 KO, sh Arl8b , and corresponding control MLO-Y4 cells, supplemented with 50 ng/mL RANKL and 30 ng/mL M-CSF ( n = 3). After 4 days of culture, qPCR was performed to evaluate mRNA expression levels of osteoclast marker genes, including Trap , DC-stamp , Ctsk , and Nfatc1 . ( D ) Representative images of tartrate-resistant acid phosphatase (TRAP)-stained osteoclast cultures ( n = 3). ( E ) TRAP-positive cells were counted based on the number of nuclei. ( F ) TRAP-positive multinucleated cells (containing > 3 nuclei) were quantified. ( G ) Cathepsin K (CTSK), a marker of osteoclasts, was detected by western blotting ( n = 3). ( H ) The mRNA expression of matrix metalloproteinase 14 ( Mmp14 ) in MLO-Y4 cells was measured by RT-qPCR ( n = 3). ( I , J ) The protein levels of MMP14 in MLO-Y4 cells were evaluated by western blotting. ( K ) Quantitative analysis of MMP14 protein expression was performed using ImageJ software. ( L )The mRNA expression of Mmp14 in the femurs of mice was assessed by qPCR ( n = 3). Data represent at least three independent experiments and are shown as mean ± S.D. (ns, not significant, * p < 0.05, ** p < 0.01, *** p < 0.001). The full-length blot is presented in supplementary Raw Western

    Article Snippet: RANKL and OPG protein levels in the supernatants were determined using the sRANKL ELISA Kit (CUSABIO, cat# CSB-E05127m) and the OPG ELISA Kit (CUSABIO, cat# CSB-E04693m), respectively.

    Techniques: Enzyme-linked Immunosorbent Assay, Cell Culture, Derivative Assay, Control, Expressing, Marker, Staining, Western Blot, Quantitative RT-PCR, Software